Antibody Drugs Could Be Next COVID-19 Milestone
DARPA Saw The Pandemic Coming – Can AbCellera Investment Pay Off?
Working with the US agency for two years, was primed to respond, and is competing with and Regeneron to bring a COVID-19 therapy to patients before the end of 2020.
You may also be interested in...
Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.
Gilead is preparing to unveil its long-term commercial plan for the antiviral therapy, including its expectations on prices and profits.